Pharmaceutical

Ipsen’s Elafibranor gains MHRA approval for PBC treatment

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.

Oct 10, 2024 - 04:00
Ipsen’s Elafibranor gains MHRA approval for PBC treatment
Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) in adults.
Read the original article

Tags:

Previous Article

City Therapeutics launches with $135m Series A funding

Next Article

Magazine: Cell and gene therapy approvals drive paradigm change in manufacturing

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: U.K. trade group suspends Novo Nordisk for ‘serious breaches’ in promoting obesity drug

STAT+: U.K. trade group suspends Novo Nordisk for ‘seri...

Mar 19, 2023

Risk adjusted net present value: What is the current va...

Jul 2, 2024

STAT+: Nick Leschly departs Bluebird Bio spinout amid restructuring, layoffs

STAT+: Nick Leschly departs Bluebird Bio spinout amid r...

Sep 12, 2023